Tests quercetin or alpha lipoic acid added to metformin in polycystic ovary syndrome
Tests adding quercetin or alpha lipoic acid to metformin in women with PCOS.
Plain-language title generated from the registry record
Registry title: Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Key facts
- Where
- Baghdad, IraqSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for newly diagnosed women with polycystic ovary syndrome (PCOS) aged 18-40 years. It tests adding Quercetin or Alpha-Lipoic Acid to metformin.
- Age
- 18-40 years
- Sex
- Women (the record lists all sexes, but the criteria describe women with PCOS)
- Disease stage
- Newly diagnosed PCOS: small cysts on both ovaries on ultrasound, periods more than 35 days apart, and signs of high male hormones such as acne or excess hair.
- Earlier treatment
- Cannot have used birth control pills, hormone therapy or cholesterol-lowering drugs.
- Biomarker or test result
- Normal prolactin (PRL) levels.
Main reasons for not taking part
- Adrenal enzyme deficiency or other hormone disease, including diabetes
- Other health problems such as high blood pressure or heart disease
- Use of birth control pills, hormone therapy or cholesterol-lowering drugs
- Pregnancy
Read by machine on 12 November 2026.
Where in Iraq
- Mustansiriyah University/ College of PharmacyBaghdad, IraqContact: Inaam Arif, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Al-Mustansiriyah University
- Trial code
- NCT07182526
- Record updated
- 19 September 2025
- Original description
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.Read full original descriptionShow less
Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.
Inclusion: • Newly diagnosed patients should be at reproductive aged from 18-40 years; Patients diagnosed with presence of micro polycystic ovaries at ultrasound; Oligomenorrhea with inter-menstrual intervals longer than 35 days; Clinical or biochemical signs of hyperandrogenism (acne, hirsutism); Normal PRL levels.
Exclusion: • Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes; Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction); Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs; Pregnant women.